• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team

    1/7/21 8:00:00 AM ET
    $TRIL
    $PHAT
    $RCKT
    $PASG
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRIL alert in real time by email

    MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and Max Nowicki to Senior Associate.

    Aditya Kohli, Ph.D., joined the Frazier Life Sciences team in 2016 and focuses on company creation. He co-founded Phathom Pharmaceuticals (NASDAQ: PHAT) and Scout Bio, and helped launch Passage Bio (NASDAQ: PASG). Dr. Kohli serves as the Chief Business Officer of Phathom Pharmaceuticals and as a member of the board of directors for Scout Bio.

    Anna Chen, Ph.D., joined Frazier in 2018 and focuses on evaluating investment opportunities and creating new ventures in the life sciences sector. She is a board observer for Amunix Pharmaceuticals and Inipharm.

    Max Nowicki, M.D., joined the Frazier Life Sciences team in 2019 and focuses on identifying new public and private investment opportunities. He has been involved in numerous Frazier investments, including Rocket Pharmaceuticals (NASDAQ: RCKT) and Trillium Therapeutics (NASDAQ: TRIL).

    “We are thrilled to announce the promotions of Aditya, Anna, and Max,” said James Topper, Managing Partner at Frazier. “They are extremely valuable members of our team, and are instrumental in helping us create new companies, as well as invest in new public and private companies.”

    About Frazier Healthcare Partners

    Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $4.8 billion total capital raised, Frazier has invested in over 200 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe.

    For more information about Frazier Healthcare Partners, visit the company's website at http://www.frazierhealthcare.com.

    Get the next $TRIL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRIL
    $PHAT
    $RCKT
    $PASG

    CompanyDatePrice TargetRatingAnalyst
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/30/2025$5.00Outperform → In-line
    Evercore ISI
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/28/2025Overweight → Neutral
    Analyst
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/28/2025$2.00Neutral → Sell
    Goldman
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/28/2025$8.00Outperform → Market Perform
    Leerink Partners
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/28/2025$2.50Buy → Hold
    Jefferies
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/28/2025$7.00Overweight → Equal-Weight
    Morgan Stanley
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/27/2025Buy → Hold
    TD Cowen
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/27/2025Buy → Hold
    Needham
    More analyst ratings

    $TRIL
    $PHAT
    $RCKT
    $PASG
    SEC Filings

    See more
    • Passage Bio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Passage BIO, Inc. (0001787297) (Filer)

      5/30/25 4:25:09 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rocket Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ROCKET PHARMACEUTICALS, INC. (0001281895) (Filer)

      5/27/25 7:40:06 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Rocket Pharmaceuticals Inc.

      144 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

      5/16/25 4:13:14 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Financials

    Live finance-specific insights

    See more
    • Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease

      Conference call to be held later today at 8:30 a.m. ET Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare diseases, today announced an update related to RP-A501, its investigational gene therapy for Danon disease. A patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected Serious Adverse Event (SAE). The SAE involved clinical complications related to a capillary leak syndrome. Rocket is conducting a comprehensive root cause analysis and remains in active dialogue with the U.S. Food and Drug Administration (FDA) and other key stakeholders, with the c

      5/27/25 7:00:00 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providersNet revenues of $28.5 million reported for Q1Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwindsStrategic cost reductions and executive leadership changes implemented to support sustainable revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026Management to host conference call today, May 1, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commerciali

      5/1/25 7:00:41 AM ET
      $ITCI
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

      • Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recordi

      4/23/25 8:00:22 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Kapadia Sandip

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      5/30/25 9:41:02 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Gowen Maxine

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      5/30/25 7:31:13 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Countouriotis Athena

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      5/30/25 7:30:26 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease

      Conference call to be held later today at 8:30 a.m. ET Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare diseases, today announced an update related to RP-A501, its investigational gene therapy for Danon disease. A patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected Serious Adverse Event (SAE). The SAE involved clinical complications related to a capillary leak syndrome. Rocket is conducting a comprehensive root cause analysis and remains in active dialogue with the U.S. Food and Drug Administration (FDA) and other key stakeholders, with the c

      5/27/25 7:00:00 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy

      RP-A601 was generally well-tolerated at a dose of 8.0E13 GC/kg with no dose-limiting toxicities in all three patients with up to 12 months follow-up RP-A601 promoted increased protein expression and desmosomal localization of Plakophilin-2 (PKP2), Desmocollin-2, and Cadherin-2 in all three patients Improvement or stabilization observed in arrhythmia burden, heart function, and quality of life in all patients No further dose escalation planned Investor webinar to be held later today at 4:30 p.m. ET Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need,

      5/15/25 3:15:00 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

      FLORHAM PARK, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that the company is scheduled to participate in the following investor conferences in May and June: H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ in New York, NYDate: Tuesday, May 20, 2025Live Webcast: 4:00 p.m. ETCompany to participate in one-on-one meetings throughout the conference Jefferies Global Healthcare Conference in New York, NYDate: Thursday, June 5, 2025Live Webcast: 9:55 a.m. ETCompany to participate in one-on-one meetin

      5/15/25 7:59:54 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Rocket Pharmaceuticals from Outperform to In-line and set a new price target of $5.00

      5/30/25 10:04:19 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals downgraded by Analyst

      Analyst downgraded Rocket Pharmaceuticals from Overweight to Neutral

      5/28/25 3:12:28 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals downgraded by Goldman with a new price target

      Goldman downgraded Rocket Pharmaceuticals from Neutral to Sell and set a new price target of $2.00

      5/28/25 9:38:28 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Topper James N bought $14,609 worth of shares (3,780 units at $3.86) (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/23/25 4:06:35 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Topper James N bought $24,462 worth of shares (7,420 units at $3.30) (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/15/25 4:17:38 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Topper James N bought $152,917 worth of shares (48,203 units at $3.17) (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/13/25 4:13:04 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for VOQUEZNA issued to PHATHOM PHARMACEUTICALS INC

      Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

      7/18/24 10:52:01 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VOQUEZNA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC

      Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA TRIPLE PAK (ORIG-1) with active ingredient AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215152, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

      5/11/22 10:51:07 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VOQUEZNA DUAL PAK issued to PHATHOM PHARMACEUTICALS, INC

      Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA DUAL PAK (ORIG-1) with active ingredient AMOXICILLIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215153, Application Classification: Type 5 - New Formulation or New Manufacturer

      5/11/22 10:17:03 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Leadership Updates

    Live Leadership Updates

    See more
    • Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, the Company's Board of Directors has approved the grant of inducement awards. On May 1, 2025, the Company's Board of Directors granted inducement awards to Mr. Bentley under the Company's 2025 Employment Inducement Incentive Award Plan (the "Inducement Plan"). Mr. Bentley was granted a non-qualified stock option to purchase 79,365 shares of Phathom common

      5/1/25 4:15:59 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Frazier Life Sciences Appoints Aditya Kohli to Partner

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ:HLVX, IPO in 2022)), Phathom Pharmaceuticals (NASDAQ:PHAT, IPO in 2019)), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to se

      4/17/25 8:00:00 AM ET
      $HLVX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

      FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of building and scaling commercial organizations, bringing new therapies to market, and successfully guiding companies through key business milestones and strategic transactions. "We are pleased to welcome Ted to the Phathom Board during a pivotal period for the com

      4/16/25 8:00:46 AM ET
      $CDTX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Rocket Pharmaceuticals Inc.

      SC 13D/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

      12/16/24 7:51:51 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Passage Bio Inc.

      SC 13G - Passage BIO, Inc. (0001787297) (Subject)

      11/14/24 12:03:11 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rocket Pharmaceuticals Inc.

      SC 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

      11/8/24 10:52:38 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care